Trial Profile

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SLATE 001 (Primary) ; TCR-transduced lymphocytes (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
Indications Advanced breast cancer; Colorectal cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

17 May 2024 Planned initiation date (estimated date of first participant enrollment) changed to 23 May 2024.
25 Apr 2024 Planned initiation date changed from 30 Apr 2024 to 1 May 2024.
24 Apr 2024 Planned initiation date (estimated date of first participant enrollment) changed to 30 Apr 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com